Back to Best of 2018 - Breast cancer, bone health and bisphosphonates: breaking down the role of bone-modifying agents in adjuvant breast cancer and STEMPEDE into CHAARTED territory: updates on treatment of castrate-sensitive prostate cancer
Best of 2018 - Breast cancer, bone health and bisphosphonates: breaking down the role of bone-modifying agents in adjuvant breast cancer and STEMPEDE into CHAARTED territory: updates on treatment of castrate-sensitive prostate cancer

Best of 2018 - Breast cancer, bone health and bisphosphonates: breaking down the role of bone-modifying agents in adjuvant breast cancer and STEMPEDE into CHAARTED territory: updates on treatment of castrate-sensitive prostate cancer

Speakers:

Kelly Gaertner, PharmD BCOP BCPS

Catherine Lee, PharmD BCOP BCPS

Product Details

Breast Cancer, Bone Health, and Bisphosphonates: Breaking Down the Role of Bone-Modifying Agents in Adjuvant Breast Cancer

This presentation will discuss currently available or pending literature surrounding the rationale for and use of bone-modifying agents in the adjuvant treatment of breast cancer, including the literature supporting recommendations set forth in the 2017 guidelines published by Cancer Care Ontario and the American Society of Clinical Oncology. The discussion will include background for the use of bonemodifying agents in the adjuvant treatment of early-stage breast cancer, dissection of key trials on use in the adjuvant setting, areas of controversy, and current gaps in the literature, such as use of specific bone-modifying agents, timing, and duration of therapy. Key trials discussed will include ABCSG-12, AZURE/BIG 1-04, and the EBCTCG meta-analyses. The presentation will also briefly identify additional roles of bone-modifying agents in the adjuvant breast cancer treatment setting. The goal is for the audience to understand the available data and key literature behind the guideline recommendations to assist with implementing them in clinical practice. This session is directed toward beginning or advanced practitioner pharmacists practicing in an adult oncology setting that includes breast cancer patients.

STAMPEDE into CHAARTED Territory: Updates on the Treatment of Castrate- Sensitive Prostate Cancer

The treatment landscape for hormone-sensitive prostate cancer has been transformed recently by new research using additional systemic therapies combined with androgen deprivation therapy. This session will discuss the recent advancements in castrate-sensitive prostate cancer with agents such as abiraterone acetate and docetaxel. Use of systemic agents earlier in the treatment continuum of prostate cancer is not without consequences, and the long-term clinical effects of combination therapy will be reviewed.

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member